The IBD SmartSelect Composite Rating for Hims & Hers Health increased from 93 to 96 Thursday.
Discover The 3 Keys To Successful Stock Investing
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
Hims & Hers Health is not currently near a proper buy point. See if the stock goes on to form a new base and offer a new buying opportunity.
The stock has an 80 EPS Rating, which means its recent quarterly and annual earnings growth tops 80% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q2, the company reported 183% EPS growth. Sales growth fell to 73%, down from 111% in the previous quarter.
Hims & Hers Health earns the No. 3 rank among its peers in the Medical-Services industry group. GeneDx Holdings is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
